Could RO7851624, newly into clinical trials, be RG6735?
ApexOnco Front Page
Recent articles
The company sidelines CDK2 and pan-KRAS blockers, among other projects.
Car-T therapies and ADCs feature among recent first-in-human study entrants.
Varegacestat’s pivotal study reads out imminently.
The group will take HRS-4642 into a Chinese phase 3 in first-line pancreatic cancer.
The pivotal Harmoni-GI3 study has started enrolling patients.
Readout of the Preserve-003 trial in post-PD-(L)1 NSCLC is due in December.
ASH and SABCS approach.
